Literature DB >> 7449378

Blood coagulation and idiopathic thromboembolism among fertile women.

N A Dreyer, S V Pizzo.   

Abstract

A case-control study of fibrinolytic activity and antithrombin-III (AT-III) was conducted comparing 16 women within the childbearing ages who had a recent history of idiopathic thromboembolism to 29 age- and race-matched female controls without a history of thromboembolism. All subjects had stopped using oral contraceptives at least 12 months prior to study. No difference in AT-III was evident between cases and controls. The mean fibrinolytic response to venous occlusion in cases was significantly lower; however, baseline fibrinolysis was essentially identical. These data demonstrated a bimodal distribution of fibrinolytic response among controls. By dichotomizing fibrinolytic response between the two modes in the controls, we estimated that the rate of low fibrinolytic response was 6 times as frequent in cases as controls. Thus, low fibrinolytic response may signal a natural predisposition to thromboembolism which could be triggered by use of synthetic estrogens.

Entities:  

Keywords:  Age Factors; Biology; Blood Coagulation Effects; Clinical Research; Diseases; Embolism; Fibrinolysis--analysis; Hematological Effects; Hemic System; Physiology; Research Methodology; Smoking; Thromboembolism; Vascular Diseases

Mesh:

Substances:

Year:  1980        PMID: 7449378     DOI: 10.1016/0010-7824(80)90057-8

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  3 in total

1.  Oral contraceptives and thromboembolic disease.

Authors:  S V Pizzo
Journal:  West J Med       Date:  1986-09

2.  Factors that influence the outcome of primary pulmonary hypertension.

Authors:  A Rozkovec; P Montanes; C M Oakley
Journal:  Br Heart J       Date:  1986-05

Review 3.  Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis.

Authors:  Yun-Jiu Cheng; Zhi-Hao Liu; Feng-Juan Yao; Wu-Tao Zeng; Dong-Dan Zheng; Yu-Gang Dong; Su-Hua Wu
Journal:  PLoS Med       Date:  2013-09-17       Impact factor: 11.069

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.